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C-type natriuretic peptide inhibits mesangial cell proliferation and
matrix accumulation in vivo. Local C-type natriuretic peptide (CNP)
production and CNP receptor expression have been demonstrated in
glomeruli. However, the glomerular (patho-)physiological functions of
CNP are largely unknown. We therefore investigated the effects of CNP
on mesangial cell proliferation and matrix accumulation in the rat
mesangioproliferative anti-Thy 1.1 model. Over seven days rats received a
continuous infusion (1 mg/kg/min) of either CNP (N 5 6), an irrelevant
control peptide (N 5 3) or buffer alone (N 5 6). Kidney biopsies were
performed on days 2, 4 and 8. Few significant differences between the
groups were noted on days 2 and 4. Compared to buffer treated rats on
day 8, those receiving CNP showed a 35% reduction of glomerular
mitoses, a 62% reduction of glomerular uptake of the thymidine analogue
BrdU and a significant reduction in glomerular expression of PDGF
B-chain. Double immunoperoxidase staining also revealed blunting of
proliferating, activated mesangial cells (51% reduction of a-smooth
muscle actin-/BrdU-positive cells) and macrophage influx. Moreover,
there was a marked reduction of mesangial collagen IV and fibronectin
accumulation at the protein and mRNA level. Rats receiving the control
peptide were indistinguishable from buffer treated rats. Systemic blood
pressure was reduced by 10 to 20% in both CNP and control peptide
treated rats on day 8, excluding that the findings were due to hemody-
namic effects of CNP. Our findings demonstrate that CNP is involved in
the regulation of mesangial cell proliferation and matrix production in
vivo. The data suggest the existence of a glomerular natriuretic peptide
system that may regulate tissue homeostasis and contribute to resolution
of mesangioproliferative diseases.
C-type natriuretic peptide (CNP), a recently identified member
of the natriuretic peptide family, was initially isolated from brain
[1] and hence thought to be a neurotransmitter. Later studies,
however, have detected CNP in human plasma and demonstrated
its production, among others, in glomeruli, parts of the renal
vasculature (vasa recta bundles and arcuate arteries) as well as in
the wall of large extrarenal vessels [2–4]. It was also shown to be
expressed by macrophages [5]. CNP exerts biological actions via
the natriuretic peptide B-type guanyl cyclase-linked receptor
(ANPR-B) and induction of the second messenger cGMP. The
expression of ANPR-B transcripts in glomeruli has been de-
scribed, but low copy numbers prevented a more definitive
intraglomerular localization of the receptor [2, 4, 6]. However, in
vitro ANP B-receptors as well as CNP-inducible cGMP produc-
tion were demonstrated in glomerular mesangial and epithelial
cells [7, 8].
The biological role(s) of CNP in the kidney are not yet fully
understood. Unlike the two other natriuretic peptides ANP and
BNP, its natriuretic and diuretic effects appear limited and its
vasorelaxant action in arterial vessels is significantly lower than
that of ANP and BNP [9, 10]. In recent studies, potent antipro-
liferative effects of CNP on vascular smooth muscle cells have
been reported both in vitro and in vivo [11, 12]. Given the
similarities of mesangial cells and vascular smooth muscle cells,
the actions of CNP have also been investigated in the former cell
type. However, so far no effect of CNP on the growth of cultured
human mesangial cells has been detected [8]. Effects of CNP on
mesangial cells in vivo have not yet been elucidated.
Mesangial cell proliferation and matrix accumulation charac-
terize various progressive human glomerular diseases like IgA
nephropathy, membranoproliferative glomerulonephritis, variants
of idiopathic focal sclerosis, lupus nephritis and diabetic nephrop-
athy [13, 14]. Various mediators, including platelet-derived factor
(PDGF), basic fibroblast growth factor (bFGF; FGF-2), insulin-
like growth factor-1 (IGF-1) as well as transforming growth
factor-b (TGF-b), have been identified, which induce mesangial
cell proliferation and/or matrix production in vivo [14, 15]. In
contrast, few factors are known, which downregulate these pro-
cesses (such as heparan sulphate proteoglykans, ANP) [14, 15].
Given the CNP data described above, we asked whether CNP
might represent a member of this latter group. To address this
question, we examined the effects of exogenous CNP administra-
tion on mesangial cell proliferation and matrix accumulation in
the rat model of anti-Thy 1.1 mesangioproliferative nephritis. In
this model, rats receive a bolus injection of a complement-fixing,
anti-mesangial cell (anti-Thy 1.1) antibody. Following an early
phase of mesangial dissolution (“mesangiolysis”), overshooting
mesangial cell growth and matrix production occur, which give
rise to the pathological picture of mesangioproliferative glomer-
ulonephritis [15].
METHODS
Mesangial cell culture experiments
Rat mesangial cells were established in culture, characterized
and maintained as described previously [16]. To examine the
antiproliferative effect of CNP (CNP1-22; Bachem, Heidelberg,
Germany) on the cultured mesangial cells, cells were seeded in 24
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well plates (Nunc, Wiesbaden, Germany) and grown to subcon-
fluency. They were then growth arrested for 72 hours in medium
containing 0.5% FCS. After 72 hours, the medium was replaced
by fresh medium containing 10% FCS plus various concentrations
of CNP. Cell proliferation was determined using [3H]-thymidine
(Amersham, Braunschweig, Germany) incorporation rates, 18
hours after addition of the stimulus as described [17].
Experimental design
All animal experiments were approved by the local review
board. Male Wistar rats (Charles River, Sulzfeld, Germany)
weighing 160 to 180 g at the start of the study were used for all
experiments.
Anti-Thy 1.1 mesangial proliferative glomerulonephritis was
induced by injection of a monoclonal anti-Thy 1.1 antibody (clone
OX7; European Collection of Animal Cell Cultures, Salisbury,
UK). Rats received 1 mg OX7 IgG per kg body wt intravenously
at the start of the experiment. Twenty-four hours later, micro-
osmotic pumps (model Alzet 2001, Charles River, Sulzfeld, Ger-
many) were implanted subcutaneously and the rats received a
continuous infusion of either CNP (1 mg/kg/min 5 0.5 nM/kg/min;
N 5 6), an irrelevant control peptide (see below; N 5 3) or buffer
alone (PBS containing 5 mM HCl, 5% D-glucose and 100 mg/ml
mannitol; N 5 6) over seven days. The irrelevant 28 amino acid
control peptide (a kind gift of the Niedersa¨chsisches Institut fu¨r
Peptidforschung, Hannover, Germany) had a molecular weight of
3486 Daltons, comparable to that of CNP (22 amino acids, 2197
Daltons) and a similar amino acid composition. Pilot experiments
(kindly performed by Dr. M. Meyer, Niedersa¨chsisches Institut
fu¨r Peptidforschung) had demonstrated that the loop-structure of
CNP, which is based on a disulfide-bond and determines biolog-
ical activity, remained unchanged when the peptide was stored at
37°C for seven days.
Twenty-four hour urine collections were performed on days 3
and 7 after disease induction. Surgical (maximum 2 per rats) or
autoptic renal cortical biopsies were performed on days 2, 4 and 8
after disease induction. Systolic arterial pressure was measured in
conscious restrained rats by tail-cuff plethysmography on days 21,
3 and 7. The thymidine analog 5-bromo-29-deoxyuridine (BrdU;
Sigma, Deisenhofen, Germany) was injected intraperitoneally at
one hour prior to sacrifice on day 8. Following the renal biopsies
on day 8, glomeruli were isolated and glomerular RNA was
extracted.
In the kidney biopsies, the number of glomerular mitoses, the
degree of mesangiolysis, the frequency of glomerular microaneu-
rysms and the number of apoptotic cells in glomeruli were
determined. In addition, immunostaining and in situ hybridization
were performed to detect glomerular expression of the interme-
diate filament protein a-smooth muscle actin, infiltrating cells
(monocytes/macrophages) and extracellular matrix proteins (type
IV collagen, fibronectin).
Renal morphology
Tissue for light microscopy was fixed in methyl Carnoy’s
solution [18] and embedded in paraffin. Four micrometer sections
were stained with the periodic acid-Schiff (PAS) reagent and
counterstained with hematoxylin. For each biopsy the number of
mitoses in over 30 cross sections (range 30 to 100) of consecutive
cortical glomeruli containing more than 20 discrete capillary
segments each, was evaluated by one of the authors, who was
unaware of the origin of the slides. The percentage of glomeruli
with microaneurysms were counted. The degree of mesangiolysis
was scored as described previously [16].
Immunoperoxidase staining
Four micrometer sections of methyl Carnoy’s fixed biopsy tissue
were processed by an indirect immunoperoxidase technique as
previously described [18]. Primary antibodies included:
• BU-1, a murine monoclonal antibody against bromo-de-
oxyuridine [19] containing nuclease in Tris buffered saline (Am-
ersham, Braunschweig, Germany).
• 1A4 (Dako, Glostrup, Denmark), a murine monoclonal IgG2a
antibody to an NH2-terminal synthetic decapeptide of a-smooth
muscle actin [20].
• PGF-007 (Mochida Pharmaceutical, Tokyo, Japan) a murine
monoclonal antibody to a 25 amino acid peptide located near the
COOH-terminus of the human PDGF B-chain (kind gift of
Mochida Pharmaceutical) [21].
• ED1 (Camon, Wiesbaden, Germany), a murine monoclonal
IgG antibody to a cytoplasmic antigen present in monocytes,
macrophages and dendritic cells [22].
• Affinity purified polyclonal goat anti-human/bovine type IV
collagen IgG preabsorbed with rat erythrocytes (Biozol, Birming-
ham, AL, USA).
• An affinity-purified IgG fraction of a polyclonal rabbit anti-rat
fibronectin antibody (Chemicon, Temecula, CA, USA).
For all biopsies, negative controls consisted of substitution of
the primary antibody with equivalent concentrations of an irrele-
vant murine monoclonal antibody or normal rabbit or goat IgG.
For the evaluation of the immunoperoxidase stains, the num-
bers of BrdU positive cells and ED1 positive cells per glomerular
cross section were counted as described above. Glomerular stain-
ing for a-smooth muscle actin, PDGF B-chain, fibronectin, and
type IV collagen was evaluated using a semiquantitative scoring
system and the mean score per biopsy was calculated. Each score
reflects mainly changes in the extent rather than intensity of
glomerular staining and depends on the percentage of the glo-
merular tuft area showing positive staining: 0 5 absent staining or
less than 5% of area stained; I 5 5 to 25%; II 5 25 to 50%; III 5
50 to 75%; IV 5 .75%. We have previously shown that the above
scoring system is not only reproducible among different observers,
but that the data obtained are highly correlated with those
obtained by computerized morphometry [23, 24].
Immunohistochemical double-staining
Double immunostaining for the identification of the type of
proliferating cells was performed as reported previously [24] by
first staining the sections for proliferating cells with the bromo-
deoxyuridine antibody (see above) using an immunoperoxidase
procedure. Sections were then incubated with the IgG1 monoclo-
nal antibody a-SM1 against a-smooth muscle actin using an
immunoalkaline phosphatase procedure. Cells were identified as
proliferating mesangial cells if they showed positive nuclear
staining for BrdU and if the nucleus was completely surrounded
by cytoplasm positive for a-smooth muscle actin. Negative con-
trols included omission of either of the primary antibodies, in
which case no double-staining was noted.
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TUNEL staining for the detection of glomerular cell death
In situ detection of apoptotic cell death was performed using
terminal desoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) as described [25]. Briefly, 4 mm sections of
formaldehyde fixed tissue were deparaffinized, rehydrated and
submitted to microwave antigen retrieval in citric acid buffer.
Nuclear proteins were then stripped using proteinase K (Boehr-
inger Mannheim, Germany). Next, the slides were incubated with
terminal desoxynucleotidyl transferase (Pharmacia, Freiburg,
Germany) and biotin-14-dATP (Gibco BRL, Eggenstein, Ger-
many) for one hour at room temperature. After washing, incor-
porated biotinylated ATP was detected using the ABC kit (Vec-
tor, Burlingame, CA, USA) and diaminobenzidine (DAB) plus
nickel. Slides were then counterstained with methyl green and
coverslipped. Positive controls included a DNAse control (DNAse
1; Sigma), in which all nuclei exhibited positive staining. For
negative controls, biotin-14-ATP was omitted resulting in no
nuclear staining.
In situ hybridization for type IV collagen mRNA
In situ hybridization was performed on 4 mm sections of biopsy
tissue fixed in buffered 10% formalin utilizing a digoxigenin-
labeled anti-sense RNA probe for type IV collagen [26] as
described [27]. Detection of the RNA probe was performed with
an alkaline phosphatase coupled anti-digoxigenin antibody (Ge-
nius Nonradioactive Nucleic Acid Detection Kit; Boehringer-
Mannheim) with subsequent color development. Controls con-
sisted of hybridization with a sense probe to matched serial
sections, by hybridization of the anti-sense probe to tissue sections
that had been incubated with RNAse A before hybridization, or
by deletion of the probe, antibody or color solution [27]. Glomer-
ular mRNA expression was semiquantitatively assessed using the
scoring system described above.
Northern blots
Glomeruli were isolated by differential sieving [28]. All glomer-
ular isolates were checked microscopically and exhibited a purity
of greater than 98%. Total RNA was extracted from glomeruli
with guanidinium isothiocyanate and subsequent ultracentrifuga-
tion through caesium chloride using standard procedures [29, 30].
The RNA content of the samples obtained was determined by UV
spectrophotometry at 260 and 280 nm. Samples with an OD
260/280 nm ratio of ,1.8 were discarded. Northern analysis for
the glomerular expression of a1(IV) collagen mRNA was per-
formed using digoxigenin labeled riboprobes and the Digoxigenin
Nucleic Acid Detection Kit (Boehringer) as described previously
[26]. For the detection of PDGF B-chain mRNA, a 326 bp
EcoRI/BamHI fragment of murine PDGF B cDNA [27] was
labeled with 32P using random primers. Ten micrograms of total
glomerular RNA were then fractionated by electrophoresis in a
1% agarose gel containing formaldehyde and transferred to a
Nylon membrane (Amersham, Braunschweig, Germany). Hybrid-
ization was carried out in 520 mM sodium phosphate (pH 7.2), 7%
SDS, 1 mM EDTA and 0.15 mM BSA at 60°C for 16 hours. After
hybridization, the filter was washed with 40 mM sodium phosphate
(pH 7.2), 1 mM EDTA and 1% SDS at 60°C for 30 minutes. It was
then exposed to a Kodak X-ray film at 280°C in the presence of
an intensifying screen. Stripping of the hybridization signal be-
tween the hybridization steps with the PDGF-B probe and a probe
for a housekeeping gene (1.2 kb PstI fragment of rat glyceralde-
hyde-3-phosphate-dehydrogenase (GAPDH) cDNA) was per-
formed by boiling the filter in 0.1% SDS for four minutes. Blots
were evaluated by densitometry as described [26].
Statistical analysis
All values are expressed as mean 6 SD. Statistical significance
(defined as P , 0.05) was evaluated using ANOVA and Bonfer-
roni t-tests.
RESULTS
C-type natriuretic peptide inhibits rat mesangial cell
proliferation in vitro
C-type natriuretic peptide (CNP) inhibited [3H]-thymidine in-
corporation in a concentration-dependent manner after 18 hours
of incubation (Fig. 1). [3H]-thymidine incorporation into the rat
mesangial cells was decreased to 70% of controls by 10 mM CNP.
Similar reduction rates were also noted in the MTT assay, which
detects total numbers of viable cells, where 10 mM CNP led to a
61% reduction of the extinction. Trypan blue dye exclusion was
found to be . 95% for both control and CNP treated cells,
suggesting that the reduction of [3H]-thymidine incorporation was
not due to a cytotoxic effect of the CNP.
Fig. 1. Effect of C-type natriuretic peptide (CNP) on the growth of
cultured rat mesangial cells. Dose-response relationship of CNP-induced
inhibition of [3H]-thymidine incorporation. Values are expressed as
percentage of [3H]-thymidine incorporation in mesangial cells not exposed
to CNP.
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C-type natriuretic peptide in rat mesangioproliferative
nephritis
Following the injection of anti-Thy 1.1 antibody, buffer treated
animals developed the typical course of the nephritis, which is
characterized by early mesangiolysis on days 2 and, to a lesser
degree, day 4, and followed by a phase of mesangial cell prolifer-
ation and matrix accumulation on days 4 and, more prominently,
on day 8 [15]. Analysis of PAS-stained renal sections showed that
CNP treatment, in comparison to buffer or control peptide
infused rats, led to a reduction of mesangioproliferative changes
on day 8 with little detectable effect on days 2 and 4 (Fig. 2).
C-type natriuretic peptide reduces glomerular mesangial cell
proliferation in vivo
Glomerular cell proliferation, as assessed by counting the
number of glomerular mitoses, was not different between the
three experimental groups on days 2 and 4 after disease induction
(Fig. 3). On day 8, the number of mitoses per 100 glomeruli was
reduced by 35% in the CNP group as compared to the control
peptide and buffer group (Fig. 3). The CNP treated group also
displayed a significant reduction of glomerular BrdU positive
nuclei on day 8. These latter were reduced to 61% and 51% of the
control peptide and buffer group, respectively (Fig. 3). To inves-
tigate whether the reduced cell proliferation in CNP treated
animals resulted from increased glomerular cell death/apoptosis,
we performed TUNEL-staining on the tissue sections of day 8.
TUNEL-positive nuclei ranged from 5 to 10 per 100 glomerular
cross sections. Counts were not significantly different between the
three experimental groups (data not shown).
To specifically assess the effect of CNP on mesangial cells, we
immunostained the renal sections for a-smooth muscle actin,
which was expressed only by activated mesangial cells [28]. Again,
Fig. 2. PAS-stained renal sections obtained on
day 8 after induction of anti-Thy 1.1 nephritis
from a rat infused with buffer only (A) or C-
type natriuretic peptide (CNP) (B). Compared
to buffer infused rats, the CNP infused rat
exhibits less mesangial hypercellularity and
matrix expansion. Control peptide infused rats
were indistinguishable from buffer infused rats
(magnification 3200).
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there were no significant differences between the three groups on
days 2 and 4. However, the immunostaining scores of a-smooth
muscle actin were significantly reduced on day 8 in the CNP
treated group (Fig. 3). The effect of CNP on glomerular a-smooth
muscle actin expression was most pronounced when glomeruli
with more than 50% of the tuft stained (immunohistochemical
staining scores III and IV) were analyzed separately. The percent-
age of such glomeruli was reduced to 52 6 9% in CNP infused rats
as opposed to 83 6 8% (buffer-infused rats; P , 0.001 vs. CNP)
and 71 6 5% (control peptide-infused rats; P , 0.05 vs. CNP).
By double immunostaining for BrdU- and a-smooth muscle
actin-positive cells on day 8, we specifically assessed the effect of
CNP on proliferating, activated mesangial cells. The data showed
that CNP reduced the population of BrdU-/a-smooth muscle
actin-positive cells by 51%: buffer infused rats 0.57 6 0.14 cells
per glomerular cross sections versus 0.28 6 0.05 cells in CNP
infused rats; P , 0.05 (total numbers of BrdU positive cells per
glomerular cross section in these studies were 1.09 6 0.10 in
buffer infused rats vs. 0.55 6 0.13 in CNP infused rats; the lower
number of BrdU positive cells in these studies as compared to Fig.
3 relates to differences in staining conditions).
To investigate whether CNP reduces glomerular mesangial cell
proliferation and activation indirectly, we investigated the glomer-
ular expression of PDGF B-chain, a central mediator of mesangial
cell proliferation, which is overexpressed in anti-Thy 1.1 nephritis
[27, 31]. By immunohistochemistry, there was a diminished glo-
merular protein expression of PDGF B-chain in CNP treated
animals (Fig. 3). In contrast, Northern blotting revealed no
reduction in the glomerular mRNA expression of PDGF B-chain.
Rather, CNP treated rats displayed an increase in mRNA to 147%
of the buffer group (Table 1).
Reduction of glomerular mesangial cell proliferation did not
result in prolongation of mesangiolysis and increased microaneu-
rysm formation in the CNP treated rats as compared to the
controls (Fig. 3). Proteinuria was low on both day 3 and 7 after
disease induction and was not statistically different between the
three groups of rats (day 3, buffer 13 6 6, control peptide 8 6 1,
CNP 9 6 5 mg/24 hr; day 7, buffer 18 6 10, control peptide 21 6
10, CNP 9 6 3 mg/24 hr).
C-type natriuretic peptide reduces glomerular cell infiltration
in vivo
Monocyte/macrophage influx, as detected by the ED-1 anti-
body, was significantly reduced in the CNP rats on days 4 and 8
after disease induction, but not on day 2 (Fig. 3).
Fig. 3. Effects of C-type natriuretic peptide (CNP) on glomerular proliferation (as assessed by the number of glomerular mitoses and BrdU positive
nuclei), mesangial cell activation (as assessed by glomerular de novo expression of a-smooth muscle actin), expression of platelet-derived growth factor
(PDGF) B-chain, mesangiolysis, microaneurysm formation, and monocyte/macrophage influx in rats with anti-Thy 1.1 nephritis. Symbols are: (u)
buffer infused rats, N 5 6; (f and F) CNP infused rats, N 5 6; (M and , control peptide infused rats, N 5 3; *P , 0.05 vs. buffer infused rats; 1P ,
0.05 vs. control peptide infused rats.
Table 1. Northern blot analysis of whole glomerular RNA for the
expression of type IV collagen mRNA and PDGF B-chain mRNA in
CNP, control peptide or buffer infused rats on day 8 after disease
induction
CNP
infusion
Control peptide
infusion
Buffer
infusion
Collagen IV mRNA 72% 85% 100%
72% 95% 100%
PDGF B-chain 150% 109% 100%
mRNA 144% 130% 100%
Results of two separate experiments are presented. Data are expressed
as percentage of the optical density observed in buffer infused rats and
corrected for the expression of a housekeeping gene (GAPDH).
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C-type natriuretic peptide reduces mesangial matrix
accumulation in vivo
The glomerular immunostaining scores for the matrix compo-
nents type IV collagen and fibronectin were significantly reduced
in the CNP group as compared to buffer treated rats on day 8
after disease induction (Fig. 4). Similarly, in situ hybridization for
type IV collagen mRNA also confirmed a significant reduction of
type IV collagen production on day 8 (Figs. 4 and 5). By Northern
blot analysis the glomerular mRNA expression of collagen IV was
decreased in the CNP treated rats to 72% of the buffer group
(Table 1).
Hemodynamic effects of C-type natriuretic peptide
As shown in Figure 6, systolic arterial pressure was significantly
reduced in CNP treated rats as compared to buffer rats on day 7.
However, a similar reduction in blood pressure was also noted in
the group that had received the control peptide.
DISCUSSION
In the present study, we demonstrate that a systemic C-type
natriuretic peptide (CNP) infusion exerts various beneficial ef-
fects on the course of an experimental mesangioproliferative
glomerulonephritis. In designing such in vivo studies, a central
concern is that CNP might interfere with the disease induction
itself, particularly with the glomerular binding of the nephrito-
genic antibody. In order to avoid such problems, we initiated the
CNP treatment at 24 hours after injection of the anti-mesangial
cell antibody. In previous studies, it has been demonstrated that
anti-Thy 1.1 antibody binding to mesangial cells is maximal at one
hour [18, 32]. Therefore, neither antibody binding nor comple-
ment activation should be affected by the CNP infusion. In
support of this assumption, the degree of mesangiolysis, early
proteinuria and the early (day 2) glomerular influx of monocytes/
macrophages was not affected by CNP or the control peptide.
The first major finding of the present study was that CNP
reduces glomerular cell proliferation in anti-Thy 1.1 nephritis. In
this model, glomerular cell proliferation is largely due to prolif-
eration of mesangial cells, particularly in the late stages such as
day 8 after disease induction [18, 28]. Increased proliferation of
glomerular endothelial cells as well as some monocyte/macro-
phage proliferation have also been detected, but are mostly
confined to early phases of the disease [18, 33], that is, day 2 after
disease induction, when CNP had no effect on proliferation. This
suggests that the effect of CNP was almost exclusively on prolif-
erating mesangial cells. Further support for this hypothesis is
derived from the observation that the glomerular expression of
a-smooth muscle actin, which is exclusively produced by activated
mesangial cells [28], was reduced by CNP. In addition, our data
suggest that the reduction of glomerular hypercellularity in CNP
infused rats was due to reduced cell proliferation rather than to
increased cell removal via apoptosis, which is the major pathway
of resolution in this disease [25].
One of the central mitogens for mesangial cells is PDGF
B-chain [31]. In cell culture, induction of PDGF B-chain appears
to be an auto-/paracrine common final pathway, by which many
growth factors induce mesangial proliferation [34]. It was there-
fore of interest to investigate whether CNP might exert its
antiproliferative effect via a down-regulation of mesangial PDGF
B-chain production. While the immunohistochemical analysis
indeed demonstrated reduced expression of PDGF B-chain in
CNP treated rats, the expression of glomerular PDGF B-chain
mRNA increased mildly in the CNP group. Since glomerular
PDGF B-chain mRNA was normalized via GAPDH mRNA
expression, these data suggest that glomerular PDGF gene tran-
scription on a single cell level had increased in CNP infused rats.
It is possible that a concomitant increase in protein expression was
not detected by immunohistochemistry, since the scoring system is
targeted to evaluate the extent of staining (that is, indirectly the
number of positive cells) rather than the intensity of cellular
staining. This suggests that CNP led to a reduction of mesangial
cell proliferation independent of PDGF, which in fact may have
increased on a single cell level. Alternatively, however, our in vivo
data do not allow us to fully exclude that CNP might have induced
a post-transcriptional block in the PDGF synthesis and thereby
exerted some of its antiproliferative action via decreased transla-
tion of PDGF.
A second major finding was that CNP also reduced the glomer-
ular monocyte/macrophage counts in the late stages of the
Fig. 4. Effects of C-type natriuretic peptide (CNP) on glomerular accumulation of type IV collagen (immunohistochemistry and in situ hybridization)
and fibronectin (immunohistochemistry) in rats with anti-Thy 1.1 nephritis on day 8 after disease induction. (A) Fibronectin protein. (B) Collagen IV
protein. (C) Collagen IV mRNA. The number of rats in each experiments was: buffer, N 5 6; control peptide, N 5 3; CNP, N 5 6. *P , 0.05 versus
buffer infused rats.
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disease. Glomerular macrophage influx in the anti-Thy 1.1 nephri-
tis model has been shown to depend to a large degree on the
mesangial production of monocyte chemoattractant protein-1
(MCP-1) [35]. Further, in vitro studies are therefore warranted to
examine whether CNP can reduce the mesangial cell production
of chemotactic proteins.
Fig. 5. Glomerular type IV collagen production as assessed by immunohistochemistry (A, B, C) and in situ hybridization (D, E, F) in rats with anti-Thy
1.1 nephritis on day 8 after disease induction. While heavy collagen IV protein and mRNA overexpression is noted in the buffer treated animal (A,
D), both collagen IV protein and mRNA expression is markedly reduced in the CNP infused rats (B, E). (C) No specific staining is noted in a section
of a rat with anti-Thy 1.1 nephritis when the antibody against type IV collagen is replaced by irrelevant goat IgG. (F) No specific hybridization signal
is noted in a section of a rat with anti-Thy 1.1 nephritis when a sense probe for type IV collagen is used for in situ hybridization (magnification 3400).
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Third, the current study shows that CNP reduced glomerular
matrix accumulation. We and others have previously demon-
strated that nearly all mesangial matrix proteins are overproduced
in the anti-Thy 1.1 model [36, 37]. Immunohistochemical matrix
protein deposition in the nephritis was reduced by antagonism of
TGF-b [38] and PDGF [39] as well as by less specific inhibitors of
mesangial cell growth, such as heparins [16, 40, 41]. The present
study extends these findings by showing that CNP, similar to
decorin [38], may represent an endogenous down-regulator of
glomerular extracellular matrix synthesis (whether this effect is a
direct one of CNP on matrix synthesis or is an indirect conse-
quence of the antiproliferative activity of CNP remains to be
determined). Besides glomerular proteases [42], CNP may there-
fore play an important role in the resolution of glomerular
mesangioproliferative changes.
Apart from the glomerular effects of CNP, we also noted a
significant reduction of systemic blood pressure in CNP-infused
rats. Furthermore, others have shown that CNP, at least in the
split hydronephrotic kidney, induces vasodilation of both pre- and
postglomerular vessels [43]. Conceivably, reduction of glomerular
blood pressure might ameliorate the mesangiolytic changes and
thereby reduce the subsequent need for mesangial cell prolifera-
tion and matrix production. Several findings argue against this
possibility, however, and support our notion that the observed
effects of CNP on mesangial cells in vivo did represent direct
effects: (1) infusion of the control peptide had a similar hypoten-
sive potency, yet did not affect mesangioproliferative changes; (2)
it has previously been shown that a hydralazine-induced 20%
reduction of systemic blood pressure in rats with anti-Thy 1.1
nephritis affected neither glomerular cell proliferation, macro-
phage influx, nor matrix deposition [44].
In summary, our data identify exogenous CNP as a potent
regulator of mesangial cell proliferation, matrix production and,
potentially, chemoattractant production in vivo. Data obtained in
cultured bovine carotid endothelial cells show that in endothelial
cells the production and release of CNP is stimulated by TGF-b,
FGF-2 and inflammatory cytokines such as tumor necrosis fac-
tor-a and interleukin-1 [3]. Given that CNP is produced in
glomeruli [2–4] and that many of the aforementioned cytokines
are (over-)expressed in anti-Thy 1.1 nephritis [15, 36], it is
tempting to speculate that endogenous, locally or systemically
produced CNP might be involved in the resolution phase of the
nephritis. If this role of a glomerular natriuretic peptide system,
analogous to that of the postulated vascular natriuretic peptide
system [45], can be established through the usage of specific
CNP-antagonists, both the exogenous CNP administration and
the amplification of endogenous CNP production might become
interesting therapeutic approaches to mesangioproliferative dis-
eases.
ACKNOWLEDGMENTS
This work was supported by a grant from the “Freunde der Medizini-
schen Hochschule Hannover,” a grant from the German Research Foun-
dation (SFB 244/C12), and a Heisenberg stipend to J. Floege. The
technical assistance of Ms. Monika Kregeler and Ms. Astrid Fitter in
performing this study is gratefully acknowledged.
Reprint requests to Ju¨rgen Floege, M.D., Division of Nephrology 6840,
Medizinische Hochschule, 30623 Hannover, Germany.
E-mail: Floege.Juergen@MH-Hannover.de
REFERENCES
1. SUDOH T: C-type natriuretic peptide (CNP): A new member of
natriuretic peptide family identified in porcine brain. Biochem Biophys
Res Commun 168:863–870, 1990
2. TERADA Y, TOMITA K, NONOGUCHI H, YANG T, MARUMO F: PCR
localization of C-type natriuretic peptide and B-type receptor mRNAs
in rat nephron segments. Am J Physiol 267:F215–F222, 1994
3. OGAWA Y, ITOH H, NAKAO K: Molecular biology and biochemistry of
natriuretic peptide family. Clin Exp Pharmacol Physiol 22:49–53, 1995
4. LOHE A, YEH I, HYVER T, PRATT R, JAMISON R: Natriuretic peptide
B receptor and C-type natriuretic peptide in the rat kidney. J Am Soc
Nephrol 6:1552–1558, 1995
5. VOLLMAR AM, SCHULZ R: Expression and differential regulation of
natriuretic peptides in mouse macrophages. J Clin Invest 95:2442–
2450, 1995
6. YAMAMOTO T, FENG L, MIZUNO T, HIROSE S, KAWASAKI K, YAOITA
E, KIHARA I, WILSON CB: Expression of mRNA for natriuretic
peptide receptor subtypes in bovine kidney. Am J Physiol 267:F318–
F324, 1994
7. SUGA S, NAKAO K, HOSODA K, MUKOYAMA M, OGAWA Y, SHIRAKAMI
G, ARAI H, SAITO Y, KAMBAYASHI Y, INOUYE K, IMURA H: Receptor
selectivity of natriuretic peptide family, atrial natriuretic peptide,
brain natriuretic peptide and C-type natriuretic peptide. Endocrinol-
ogy 130:229–239, 1992
8. ZHAO J, ARDAILLOU N, LU CY, PLACIER S, PHAM P, BADRE L,
CAMBAR J, ARDAILLOU R: Characterization of C-type natriuretic
peptide receptors in human mesangial cells. Kidney Int 46:717–725,
1994
9. PROTTER AA, WALLACE AM, FERRARIS VA, WEISHAAR RE: Relaxant
effect of human brain natriuretic peptide on human artery and vein
tissue. Am J Hypertens 9:432–436, 1996
10. CHARLES CJ, ESPINER EA, RICHARDS AM, NICHOLLS MG, YANDLE
TG: Comparative bioactivity of atrial, brain, and C-type natriuretic
peptides in conscious sheep. Am J Physiol 270:R1324—R1331, 1996
11. FURUYA M, YOSHIDA M, HAYASHI Y, OHNUMA N, MINAMINO N,
KANGAWA K, MATSUO H: C-type natriuretic peptide is a growth
inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res
Commun 177:927–931, 1991
12. SHINOMIYA M, TASHIRO J, SAITO Y, YOSHIDA S, FURUYA M, OKA N,
TANAKA S, KANGAWA K, MATSUO H: C-type natriuretic peptide
inhibits intimal thickening of rabbit carotid artery after balloon
catheter injury. Biochem Biophys Res Commun 205:1051–1056, 1994
13. SLOMOWITZ LA, KLAHR S, SCHREINER GF, ICHIKAWA I: Progression of
renal disease. N Engl J Med 319:1547–1548, 1988
Fig. 6. Systolic arterial pressure measurements on days 21, 3 and 7 after
induction of anti-Thy 1.1 nephritis in rats receiving a buffer infusion (N 5
6; u), control peptide (N 5 3; ) or CNP (N 5 6; F). *P , 0.05 versus
buffer infused rats.
Canaan-Ku¨hl et al: CNP effects on mesangial cells in vivo1150
14. STRIKER LJ, PETEN EP, ELLIOT SJ, DOI T, STRIKER GE: Mesangial cell
turnover: Effect of heparin and peptide growth factors. Lab Invest
64:446–456, 1991
15. FLOEGE J, ENG E, YOUNG BA, JOHNSON RJ: Factors involved in the
regulation of mesangial cell proliferation in vitro and in vivo. Kidney
Int 43(Suppl 39):S47–S54, 1993
16. BURG M, OSTENDORF T, MOONEY A, KOCH KM, FLOEGE J: Treatment
of experimental mesangioproliferative glomerulonephritis with non-
anticoagulant heparin. Therapeutic efficacy and safety. Lab Invest
76:505–516, 1997
17. FLOEGE J, TOPLEY N, HOPPE J, BARRETT TB, RESCH K: Mitogenic
effect of platelet-derived growth factor in human glomerular mesan-
gial cells: Modulation and/or suppression by inflammatory cytokines.
Clin Exp Immunol 86:334–341, 1991
18. JOHNSON RJ, GARCIA RL, PRITZL P, ALPERS CE: Platelets mediate
glomerular cell proliferation in immune complex nephritis induced by
anti-mesangial cell antibodies in the rat. Am J Pathol 136:369–374,
1990
19. GONCHOROFF NJ, KATZMANN JA, CURRIE RM, EVANS EL, HOUCK
DW, KLINE BC, GREIPP PR, LOKEN MR: S-phase detection with an
antibody to bromodeoxyuridine. Role of DNAse pretreatment. J Im-
munol Methods 93:97–101, 1986
20. SKALLI O, ROPRAZ P, TRZECIAK A, BENZONANA G, GILLESSEN D,
GABBIANI G: A monoclonal antibody against alpha-smooth muscle
actin: A new probe for smooth muscle differentiation. J Cell Biol
103:2787–2796, 1986
21. SHIRAISHI T, MORIMOTO S, ITOH K, SATO H, SUGIHARA K, ONISHI T,
OGIHARA T: Radioimmunoassay of human platelet-derived growth
factor using monoclonal antibodies toward a synthetic 73–97 fragment
of its B-chain. Clin Chim Acta 184:65–74, 1989
22. DIJKSTRA CD, DOPP EA, JOLING P, KRAAL G: The heterogeneity of
mononuclear phagocytes in lymphoid organs: Distinct macrophage
subpopulations in the rat recognized by monoclonal antibodies ED1,
ED2 and ED3. Immunology 54:589–599, 1985
23. KLIEM V, JOHNSON RJ, ALPERS CE, YOSHIMURA A, COUSER WG,
KOCH KM, FLOEGE J: Mechanisms involved in the pathogenesis of
tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:
666–678, 1996
24. HUGO C, PICHLER R, GORDON K, SCHMIDT R, AMIEVA M, COUSER
WG, FURTHMAYR H, JOHNSON RJ: The cytoskeletal linking proteins,
moesin and radixin, are upregulated by platelet-derived growth factor,
but not basic fibroblast growth factor in experimental mesangial
proliferative glomerulonephritis. J Clin Invest 97:2499–2508, 1996
25. BAKER AJ, MOONEY A, HUGHES J, LOMBARDI D, JOHNSON RJ, SAVILL
J: Mesangial cell apoptosis: The major mechanism for resolution of
glomerular hypercellularity in experimental mesangial proliferative
nephritis. J Clin Invest 94:2105–2116, 1994
26. EITNER F, WESTERHUIS R, BURG M, WEINHOLD B, GRO¨NE HJ,
OSTENDORF T, RU¨THER U, KOCH KM, REES AJ, FLOEGE J: Role of
interleukin-6 in mediating mesangial cell proliferation and matrix
production in vivo. Kidney Int 51:69–78, 1997
27. YOSHIMURA A, GORDON K, ALPERS CE, FLOEGE J, PRITZL P, ROSS R,
COUSER WG, BOWEN-POPE DF, JOHNSON RJ: Demonstration of
PDGF B-chain mRNA in glomeruli in mesangial proliferative nephri-
tis by in situ hybridization. Kidney Int 40:470–476, 1991
28. JOHNSON RJ, IIDA H, ALPERS CE, MAJESKY MW, SCHWARTZ SM,
PRITZL P, GORDON K, GOWN AM: Expression of smooth muscle cell
phenotype by rat mesangial cells in immune complex nephritis.
Alpha-smooth muscle actin is a marker of mesangial cell proliferation.
J Clin Invest 87:847–858, 1991
29. BIRNBOIM HC: Rapid extraction of high molecular weight RNA from
cultured cells and granulocytes for Northern analysis. Nucl Acids Res
16:1487–1497, 1988
30. GLISIN V, CRKVENJAKOW R, BYUS C: Ribonucleic acid isolation by
cesium chloride centrifugation. Biochemistry 13:2633–2637, 1974
31. FLOEGE J, JOHNSON RJ: Multiple roles for platelet-derived growth
factor in renal disease. Miner Electrolyte Metab 21:271–282, 1995
32. YAMAMOTO T, WILSON CB: Quantitative and qualitative studies of
antibody-induced mesangial cell damage in the rat. Kidney Int 32:514–
525, 1987
33. IRUELA-ARISPE L, GORDON K, HUGO C, DUIJVESTIJN AM, CLAFFEY
KP, REILLY M, COUSER WG, ALPERS CE, JOHNSON RJ: Participation
of glomerular endothelial cells in the capillary repair of glomerulone-
phritis. Am J Pathol 147:1715–1727, 1995
34. SILVER BJ, JAFFER FE, ABBOUD HE: Platelet-derived growth factor
synthesis in mesangial cells: Induction by multiple peptide mitogens.
Proc Natl Acad Sci USA 86:1056–1060, 1989
35. WENZEL U, SCHNEIDER A, VALENTE AJ, ABBOUD HE, THAISS F,
HELMCHEN U, STAHL RA: Monocyte chemoattractant protein-1 me-
diates monocyte/macrophage influx in anti-thymocyte antibody-in-
duced glomerulonephritis. Kidney Int 51:770–776, 1997
36. OKUDA S, LANGUINO LR, RUOSLAHTI E, BORDER WA: Elevated
expression of transforming growth factor-beta and proteoglycan pro-
duction in experimental glomerulonephritis. Possible role in expan-
sion of the mesangial extracellular matrix. J Clin Invest 86:453–462,
1990
37. FLOEGE J, JOHNSON RJ, GORDON K, IIDA H, PRITZL P, YOSHIMURA A,
CAMPBELL C, ALPERS CE, COUSER WG: Increased synthesis of
extracellular matrix in mesangial proliferative nephritis. Kidney Int
40:477–488, 1991
38. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI
YU, PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of trans-
forming growth factor-beta protects against scarring in experimental
kidney disease. Nature 360:361–364, 1992
39. JOHNSON RJ, RAINES EW, FLOEGE J, YOSHIMURA A, PRITZL P,
ALPERS C, ROSS R: Inhibition of mesangial cell proliferation and
matrix expansion in glomerulonephritis in the rat by antibody to
platelet-derived growth factor. J Exp Med 175:1413–1416, 1992
40. FLOEGE J, ENG E, YOUNG BA, COUSER WG, JOHNSON RJ: Heparin
suppresses mesangial cell proliferation and matrix expansion in ex-
perimental mesangioproliferative glomerulonephritis. Kidney Int 43:
369–380, 1993
41. TANG WW, WILSON CB: Heparin decreases mesangial matrix accu-
mulation after selective antibody-induced mesangial cell injury. J Am
Soc Nephrol 3:921–929, 1992
42. JOHNSON RJ: The glomerular response to injury: Progression or
resolution? Kidney Int 45:1769–1782, 1994
43. ENDLICH K, STEINHAUSEN M: Natriuretic peptide receptors mediate
different responses in rat renal microvessels. Kidney Int 52:202–207,
1997
44. TSUBOI Y, SHANKLAND SJ, GRANDE JP, WALKER HJ, JOHNSON RJ,
DOUSA TP: Suppression of mesangial proliferative glomerulonephritis
development in rats by inhibitors of cAMP phosphodiesterase
isozymes types III and IV. J Clin Invest 98:262–270, 1995
45. SUGA S, NAKAO K, ITOH H, KOMATSU Y, OGAWA Y, HAMA N, IMURA
H: Endothelial production of C-type natriuretic peptide and its
marked augmentation by transforming growth factor-beta. J Clin
Invest 90:1145–1149, 1992
Canaan-Ku¨hl et al: CNP effects on mesangial cells in vivo 1151
